New drugs for treatment of attention-deficit/hyperactivity disorder

Bibliography

• ROBISON LM, SCLAR DA, GALIN RS: National trends in the prevalence of attention - deficit disorder and the prescribing of methylphenidate among school-age children: 1990-1995. Clin. Pediatr. (1999) 38:209–217.
   PubMed Web of Science ®Google Scholar
• BARKLEY RA, FISCHER M, SMALLISH L, FLETCHER K: The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J. Abnorm. Psycho]. (2002) 111:279–282.
   PubMed Web of Science ®Google Scholar
• WILENS TE, BIEDERMAN J, SPENCER TI: Attention deficit/hyperactivity disorder across the lifespan. Ann. Rev Med. (2002). 53:113–131.
   PubMed Web of Science ®Google Scholar
• •Excellent current review article on ADHD.
   Google Scholar
• BARKLEY R: Attention Deficit Hyperactivity Disorder: a Handbook for Diagnosis and Treatment, 2nd edition. Guilford Press. New York (1998).
   Google Scholar
• •Outstanding textbook summarising ADHD research.
   Google Scholar
• CHAN E, ZHAN C, HOMER CJ: Health care use and costs for children with attention deficit/hyperactivity disorder: national estimates from the medical expenditure panel survey. Arch. Pediatr. Adolesc. Med. (2002) 156:504–511.
   PubMed Web of Science ®Google Scholar
• AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text revision (DSM-IV-TR). American Psychiatric Association Press, Washington, DC (2000).
   Google Scholar
• APPLEGATE B, LAHEY BB, HART EL et al.: Validity of the age-of-onset criterion for ADHD: a report from the DSM-IV field trials. I Am. Acad. Child Adolesc. Psychiatry (1997) 36:1211–1221.
   PubMed Web of Science ®Google Scholar
• BROWN RT, FREEMAN WS, PERRIN JM et al.: Prevalence and assessment of attention deficit/hyperactivity disorder in primary care settings. Pediatrics (2001) 107:E43.
   PubMed Web of Science ®Google Scholar
• PLISZKA SR: Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: an overview. J. Clin. Psychiatry (1998) 59(Suppl. 7):50–58.
   PubMed Web of Science ®Google Scholar
• BIEDERMAN J, WILENS T, MICK E, FARAONE SV, SPENCER T: Does attention deficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence? Biol. Psychiatry (1998) 44: 269–273.
   Google Scholar
• BIEDERMAN J, WILENS T, MICK E, MILBERGER S, SPENCER T, FARAONE S: Psychoactive substance use disorder in adults with attention deficit hyperactivity disorder: effects of ADHD and psychiatric comorbidity. Am. J. Psychiatry (1995) 152:1652–1658.
   PubMed Web of Science ®Google Scholar
• MCGUFFIN P, RILEY B, PLOMIN R: Toward behavioral genomics. Science (2001) 291:1243–1249.
   Web of Science ®Google Scholar
• FARAONE SV: Genetics of child disorders: XX. ADHD, part 4: is ADHD genetically heterogenous? I. Am. Acad. Child Adolesc. Psychiatry (2000) 39:1455–1457.
   PubMed Web of Science ®Google Scholar
• MILBERGER S, BIEDERMAN J, FARAONE SV, CHEN L, JONES J: Is maternal smoking a risk factor for attention deficit hyperactivity disorder in children? Am. J. Psychiatry (1996) 153:1138–1142.
   Google Scholar
• TUTHILL RW: Hair lead levels related to children's classroom attention-deficit behavior. Arch. Environ. Health. (1996) 51:363–383.
   Google Scholar
• SUNOHARA GA, ROBERTS W, MALONE M et al.: Linkage of the dopamine D4 receptor gene and attention-deficit/hyperactivity disorder. .1 Am. Acad. Child Adolesc. Psychiatry (2000) 39:1537–1542.
   Google Scholar
• DALY G, HAWI Z, FITZGERALD M, GILL M: Mapping susceptibility loci in attention deficit hyperactivity disorder: preferential transmission of parental alleles at DAT1, DBH and DRD5 to affected children. Mol. Psychiatry (1999) 4: 192–196.
   Google Scholar
• FISHER SE, FRANCKS C, MCCRACKEN JT et al: A genomewide scan for loci involved in attention-deficit/ hyperactivity disorder. Am. I Hum. Genet. (2002) 70:1183–1196.
   PubMed Web of Science ®Google Scholar
• •First genomic scan of ADHD.
   Google Scholar
• LEIBSON CL, KATUSIC SK, BARBARESI WJ, RANSOM J, O'BRIEN PC: Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA (2001) 285:60–66.
   PubMed Web of Science ®Google Scholar
• •Seminal article on health services usage for children with ADHD.
   Google Scholar
• GUEVARA J, LOZANO P, WICKIZER T, MELL L, GEPHART H: Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder. Pediatrics (2001) 108:71–78.
   PubMed Web of Science ®Google Scholar
• BARKLEY RA, MURPHY KR, KWASNIK D: Motor vehicle driving competencies and risks in teens and young adults with attention deficit hyperactivity disorder. Pediatrics (1996) 98:1089–1095.
   PubMed Web of Science ®Google Scholar
• SZATMARI P, OFFORD DR, BOYLE MH: Correlates, associated impairments and patterns of service utilization of children with attention deficit disorder. Child Psycho]. Psychiatry (1989) 30:205–217
   PubMed Web of Science ®Google Scholar
• GREENHILL LL, HALPERIN JM, ABIKOFF H: Stimulant medications.j Am. Acad. Child Adolesc. Psychiatry(1999) 38:503–512.
   PubMed Web of Science ®Google Scholar
• •Excellent review article on stimulant medications.
   Google Scholar
• BARKELY RA, McMURRAY MB, EDELBROCK CS et al: Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo - controlled evaluation. Pediatrics (1990) 86:184–192.
   PubMed Web of Science ®Google Scholar
• SPENCER T, BIEDERMAN J, HARDINGM, O'DONNELL D, FARAONE SV, WILENS TE: Growth deficits in ADHD children revisited: evidence for disorder associated growth delays?I Am. Acad. Child Adolesc. Psychiatry (1996) 35:1460–1469.
   PubMed Web of Science ®Google Scholar
• GADOW K, SVERD J, SPRAFKIN J et al.: Long term methylphenidate therapy in children with comorbid attention deficit hyperactivity disorder and chronic multiple tic disorder. Arch. Gen. Psychiatry (1999) 56:330–336.
   PubMed Web of Science ®Google Scholar
• ELIA J: Drug treatment for hyperactive children. Therapeutic guidelines. Drugs (1993) 46:863–871.
   PubMed Web of Science ®Google Scholar
• BIEDERMAN J, WILENS T, MICK E et al.: Pharmacotherapy of attention deficit/ hyperactivity disorder reduces risk for substance use disorder. Pediatrics (1999) 104:e20.
   PubMed Web of Science ®Google Scholar
• THE MTA COOPERATIVE GROUP: A 14-month randomized clinical trial of treatment strategies for attention-deficit/ hyperactivity disorder. Arch. Gen. Psychiatry (1999) 56:1073–1086.
   PubMed Web of Science ®Google Scholar
• •Landmark study comparing stimulants to behavioural treatments for ADHD.
   Google Scholar
• PELHAM WE, GNAGY EM, BURROWS-MACLEAN L et al: Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics (2001) 107:e105.
   PubMedGoogle Scholar
• BRADLEY C: The behavior of children receiving benzedrine. Am. Psychiatry (1937) 94:577–585.
   Google Scholar
• SPENCER T, BIEDERMAN J, WILENS T et al.: Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J. Am. Acad. Child Adolesc. Psychiatry(1996) 35:409–432.
   PubMed Web of Science ®Google Scholar
• WILENS TE, BIEDERMAN J, PRINCE J et al.: Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am. Psychiatry (1996) 153: 1147–1153.
   Google Scholar
• SPENCER T, BIEDERMAN J, COFFEY B et al.: A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry(2002) 59: 649–656.
   Google Scholar
• WILENS TE, SPENCER TJ, BIEDERMAN J et al.: A controlled clinical trial of buproprion for attention deficit hyperactivity disorder in adults. Am. Psychiatry (2001) 158:282–288.
   PubMed Web of Science ®Google Scholar
• BARRICKMAN LL, PERRY PJ, ALLEN AJ et al.: Buproprion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. I Am. Acad. Child Adolesc. Psychiatry (1995) 34:649–657.
   PubMed Web of Science ®Google Scholar
• HEDGES D, REIMHERR FW, ROGERS A, STRONG R, WENDER PH: An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder. Psychopharmacol Bull. (1995) 31:779–783.
   PubMed Web of Science ®Google Scholar
• FINDLING RL, SCHWARTZ MA, FLANNERY DJ, MANOS MJ: Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. j Clin. Psychiatry (1996) 57:184–189.
   PubMed Web of Science ®Google Scholar
• CONNOR DF, FLETCHER KE, SWANSON JM: A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. I Am. Acad. Child Adolesc. Psychiatry (1999) 38:1551–1559.
   PubMed Web of Science ®Google Scholar
• STEINGARD R, BIEDERMAN J, SPENCER T, WILENS T, GONZALEZ A: Comparison of clonidine response in the treatment of attention deficit hyperactivity disorder with and without comorbid tic disorders. I Am. Acad. Child Adolesc. Psychiatry (1993) 32:350–353.
   PubMed Web of Science ®Google Scholar
• DECISION RESOURCES INC.: Study on attention-deficit/hyperactivity disorder finds novel psychostimulant formulations will drive market growth. PR Newswire. 30/01/02.
   Google Scholar
• CASTELLANOS FX, ELIA J, KRUESI MJ et al: Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with attention deficit/hyperactivity disorder. Neuropsychopharmacology (1996) 14:125–137.
   PubMed Web of Science ®Google Scholar
• SOLANTO MV: Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research. Behav. Brad) Res. (2002) 130:65–71.
   PubMed Web of Science ®Google Scholar
• ARNSTEN AF: Catecholamine regulation of the prefrontal cortex. .1. Psychopharmacol (1997) 11:151–162.
   Web of Science ®Google Scholar
• RUBIA K, OVERMEYER SO, TAYLOR E et al: Hypofrontality in attention deficit hyperactivity disorder during higher order motor control: a study with fMRI. Am. Psychiatry (1999) 156:891–896.
   PubMed Web of Science ®Google Scholar
• VOLKOW ND, WANG G, FOWLER JS et al.: Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. Neurosci. (2001) 21:RC121.
   Google Scholar
• KRAUSE KH, DRESEL SH, KRAUSE J, KUNG HF, TATSCH K: Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci. Lett. (2000) 285:107–110.
   PubMed Web of Science ®Google Scholar
• VOLKOW N, WANG G, FOWLER J et al: Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am. Psychiatry (1998) 155:1325–1331.
   PubMed Web of Science ®Google Scholar
• BIRNBAUM SG, PODELL DM, ARNSTEN AF: Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem. Behav. (2000) 67:397–403.
   PubMed Web of Science ®Google Scholar
• BIEDERMAN J, SPENCER T: Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol. Psychiatry (1999) 46:1234–1242.
   PubMed Web of Science ®Google Scholar
• MICHAELSON D, FARIES D, WERNICKE J et al.: Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics (2001) 108:E83.
   PubMed Web of Science ®Google Scholar
• KRATOCHIVIL CJ, HEILIGENSTEIN JH, DITTMANN R et al: Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. j Am. Acad. Child Adolesc. Psychiatry (2002) 41:776–784.
   PubMed Web of Science ®Google Scholar